Objectives: Determine the status of immunity against the hepatitis B virus amongvaccinated hemodialysis patients at a tertiary care hospital. Study Design: Cross sectionalstudy. Place and Duration of Study: All medical wards of Civil Hospital and Ojha campus, DowUniversity of Health Sciences, Karachi, Pakistan from May 2013 to January 2015. Methodology:Patients with chronic kidney disease on hemodialysis attending out-patient department wereenrolled. Patients with either gender and aged 18-70 years, who give consent for participation,who are on HD for more than 9 months with a proven diagnosis of ESRD who have receiveda complete course of 4 doses of hepatitis B vaccination atleast 2 months back were includedin this study. Non-consenting patients, present/past history of viral hepatitis, patients whowere hepatitis B surface antigen (HBsAg) positive, patients on immunosuppressive agents,pregnant patients were excluded from this study. Results: Out of the 103 patients, 69 (67%)males and 34 (33%) females with mean age of study population was 51.1 ± 14.3 years (17 to70 years), mean duration post vaccination was 7.6 ± 0.9 months (6 to 9 months), mean antiHBs antibody level was 184.6 ± 293.4 (level rang 0 to 1000) and mean hemodialysis durationwas 26.4 ± 12 months (10 to 50 month). Out of 37 non-responders 28 (75.7%) had twice weeklyschedule of hemodialysis and 09 (24.3%) had thrice weekly schedule of hemodialysis, out of 19weak responders 13 (68.4%) had twice weekly schedule of hemodialysis and 06 (31.6%) hadthrice weekly schedule of hemodialysis and out of 47 high responders 29 (61.7%) had twiceweekly schedule of hemodialysis and 18 (38.3%) had thrice weekly schedule of hemodialysis(p=0.395). Conclusion: Excellent response of HbsAg B vaccination for those patients, undergodialysis procedure that is not associated with age, systemic inflammation or nutritional. Effectivedialysis procedure associated with excellent response to the vaccine hepatitis B.
77 Late results of hepatitis B vaccination in hemodialysis patients
